Cargando…
Micro-laminin gene therapy can function as an inhibitor of muscle disease in the dy(W) mouse model of MDC1A
Gene replacement for laminin-α2-deficient congenital muscular dystrophy 1A (MDC1A) is currently not possible using a single adeno-associated virus (AAV) vector due to the large size of the LAMA2 gene. LAMA2 encodes laminin-α2, a subunit of the trimeric laminin-211 extracellular matrix (ECM) protein...
Autores principales: | Packer, Davin, Martin, Paul T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8026908/ https://www.ncbi.nlm.nih.gov/pubmed/33869655 http://dx.doi.org/10.1016/j.omtm.2021.02.004 |
Ejemplares similares
-
Skeletal muscle laminin and MDC1A: pathogenesis and treatment strategies
por: Gawlik, Kinga I, et al.
Publicado: (2011) -
Life or death by NFκB, Losartan promotes survival in dy(2J)/dy(2J) mouse of MDC1A
por: Elbaz, M, et al.
Publicado: (2015) -
Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy
por: Willmann, Raffaella, et al.
Publicado: (2017) -
Partial laminin alpha2 chain restoration in alpha2 chain-deficient dy/dy mouse by primary muscle cell culture transplantation
Publicado: (1996) -
Early skeletal muscle pathology and disease progress in the dy(3K)/dy(3K) mouse model of congenital muscular dystrophy with laminin α2 chain-deficiency
por: Gawlik, Kinga I., et al.
Publicado: (2019)